Kazakhstan Medical Device Technical Testing Requirements: Timelines, Exemptions and Laboratory Coordination

1. Key takeaways

Technical testing in Kazakhstan is organized by the expert organization and performed by accredited laboratories, and the scope of testing depends on the risk class, mechanism of action and technical characteristics of the product. The review procedure includes two stages, preliminary expertise and specialized expertise, with laboratory studies of samples conducted where required. Two levers matter most for speed: the exemptions from laboratory studies (devices manufactured at production sites in the European Union, the United Kingdom, the United States, Canada, Japan or Switzerland and approved for circulation by the local regulator; re-registration; the accelerated procedure; medical equipment, among others), and the reducing effect of an ISO 13485 certificate at the production inspection stage under Decision No. 106. Laboratory scheduling is usually more time-consuming than the review itself, so it deserves a separate line in the project plan rather than being folded into the statutory review clock.

2. Legal basis

3. Expert insights

Insight one: the exemption from laboratory studies is judged by manufacturing site plus approval status, a point worth repeating. Medical devices manufactured at production sites in the European Union, the United Kingdom, the United States, Canada, Japan or Switzerland, and approved for circulation by the regulatory authority of those countries, are exempt from laboratory studies. This shares the same logic as the eligibility test for the one-window accelerated channel introduced in 2026, which shortens the timeline to a minimum of 15 working days. For Chinese manufacturers with existing overseas capacity or contract manufacturing abroad, this provision has immediate practical value and should be checked at project initiation.

Insight two: re-registration and the accelerated procedure are additional exemption gateways. In re-registration scenarios, where the dossier is updated, laboratory studies need not be repeated; the accelerated procedure likewise exempts them. When planning product iterations, a company can therefore schedule new models as dossier changes rather than fresh registrations and reuse the existing test conclusions. This planning choice compounds over a product family’s lifetime and often saves an entire laboratory campaign per iteration.

Insight three: laboratory scheduling, not the review deadline, is the dominant variable in the project timeline. The statutory review timelines are 110 working days where laboratory studies are required and 70 working days where they are not. Both figures describe the review only; testing, sample shipping and inspection time are counted separately. Treating the 110 working days as the whole project duration is one of the most common scheduling errors GRZAN observes, and it routinely produces plans that are three to five months optimistic. A realistic plan treats laboratory queue time, shipping and customs as first-class schedule items with their own owners and dates.

Insight four: an ISO 13485 certificate carries weight at the production inspection stage, but not at the technical testing stage. Under Decision No. 106, where the manufacturer has established a quality management system equivalent to ISO 13485, the inspection may be limited to design and development, production and release control, and consumer-related processes including post-market surveillance. This reduction applies only to the inspection, however. It does not shorten or waive technical testing, and conflating the two benefits leads to faulty project budgets.

Insight five: confirm the reporting conventions with the laboratory in advance. The selection of test items, the acceptance criteria and the report format can differ between laboratories. Confirming them in writing before samples are shipped avoids the painful rework scenario in which a report is issued but the reviewer does not accept it, forcing a repeat campaign, a second fee cycle and a lost season in the market.

4. Practical recommendations

1. At project initiation, first determine whether the exemption from laboratory studies applies, focusing on the manufacturing site and the approval status.
2. Budget the laboratory schedule as a separate line and never merge it with the statutory review timeline.
3. Confirm the test items, acceptance criteria and report format with the laboratory in writing before samples are shipped.
4. Where an ISO 13485 certificate exists, prepare the reduction package for the production inspection, including the certificate and audit reports.
5. Wherever possible, plan product iterations as dossier changes so that existing test conclusions can be reused.

5. Verification checklist

• □ Exemption from laboratory studies has been assessed (manufacturing site plus approval status, plus re-registration and the accelerated procedure)
• □ The laboratory schedule is budgeted separately and has not been merged with the review timelines of 110 / 70 working days
• □ Test items, acceptance criteria and report format have been confirmed with the laboratory in writing
• □ Sample quantity and remaining shelf life meet the requirements
• □ ISO 13485 certificate and audit reports are prepared for the production inspection reduction
• □ Iteration models have been assessed for treatment as dossier changes

GRZAN provides registration support in Kazakhstan for manufacturers, importers and authorized representatives, covering technical testing strategy, laboratory coordination, expert review liaison and post-approval maintenance. For assistance, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.